Literature DB >> 25641676

Vaccination approach to anti-angiogenic treatment of cancer.

Madelon Q Wentink1, Elisabeth J M Huijbers1, Tanja D de Gruijl1, Henk M W Verheul1, Anna-Karin Olsson2, Arjan W Griffioen3.   

Abstract

Improvement of patient survival by anti-angiogenic therapy has proven limited. A vaccination approach inducing an immune response against the tumor vasculature combines the benefits of immunotherapy and anti-angiogenesis, and may overcome the limitations of current anti-angiogenic drugs. Strategies to use whole endothelial cell vaccines and DNA- or protein vaccines against key players in the VEGF signaling axis, as well as specific markers of tumor endothelial cells, have been tested in preclinical studies. Current clinical trials are now testing the promise of this specific anti-cancer vaccination approach. This review will highlight the state-of-the-art in this exciting field of cancer research.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Angiogenesis; Immunology; Tumor vasculature; Vaccination

Mesh：

Substances：

Year:  2015        PMID： 25641676     DOI： 10.1016/j.bbcan.2015.01.005

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN： 0006-3002


  14 in total

1.  Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice.

Authors:  Kellsye Paula L Fabian; Nina Chi-Sabins; Jennifer L Taylor; Ronald Fecek; Aliyah Weinstein; Walter J Storkus
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

2.  Reply to Marchiò et al.: Antitumor immune regulation by angiostatic therapy.

Authors:  Madelon Q Wentink; Elisabeth J M Huijbers; Peter Timmerman; Arjan W Griffioen
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-11       Impact factor: 11.205

3.  Targeting Fibronectin for Cancer Imaging and Therapy.

Authors:  Zheng Han; Zheng-Rong Lu
Journal:  J Mater Chem B       Date:  2016-12-01       Impact factor: 6.331

Review 4.  Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.

Authors:  Kabir A Khan; Robert S Kerbel
Journal:  Nat Rev Clin Oncol       Date:  2018-02-13       Impact factor: 66.675

5.  Targeted vaccination against the bevacizumab binding site on VEGF using 3D-structured peptides elicits efficient antitumor activity.

Authors:  Madelon Q Wentink; Tilman M Hackeng; Sebastien P Tabruyn; Wouter C Puijk; Klaus Schwamborn; Daniele Altschuh; Rob H Meloen; Teun Schuurman; Arjan W Griffioen; Peter Timmerman
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

6.  Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy.

Authors:  Judy R van Beijnum; Elisabeth J M Huijbers; Karlijn van Loon; Athanasios Blanas; Parvin Akbari; Arno Roos; Tse J Wong; Stepan S Denisov; Tilman M Hackeng; Connie R Jimenez; Patrycja Nowak-Sliwinska; Arjan W Griffioen
Journal:  Nat Commun       Date:  2022-05-23       Impact factor: 17.694

Review 7.  Direct and indirect regulation of the tumor immune microenvironment by VEGF.

Authors:  Yuqing Zhang; Rolf A Brekken
Journal:  J Leukoc Biol       Date:  2022-04-25       Impact factor: 6.011

8.  Role of angiogenesis in adenomyosis-associated abnormal uterine bleeding and subfertility: a systematic review.

Authors:  Marissa J Harmsen; Caroline F C Wong; Velja Mijatovic; Arjan W Griffioen; Freek Groenman; Wouter J K Hehenkamp; Judith A F Huirne
Journal:  Hum Reprod Update       Date:  2019-09-11       Impact factor: 15.610

Review 9.  Anti-angiogenic alternatives to VEGF blockade.

Authors:  Kabir A Khan; Roy Bicknell
Journal:  Clin Exp Metastasis       Date:  2015-11-30       Impact factor: 5.150

10.  Immunogenicity and safety of xenogeneic vascular endothelial growth factor receptor-2 DNA vaccination in mice and dogs.

Authors:  Sofie Denies; Laetitia Cicchelero; Ingeborgh Polis; Niek N Sanders
Journal:  Oncotarget       Date:  2016-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.